Search Results - "Polman, Chris H"

Multiple sclerosis: current knowledge and future outlook by Kamm, Christian P, Uitdehaag, Bernard M, Polman, Chris H

“…Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and axonal loss. The etiology of MS is…”
Get more information

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria by Polman, Chris H., Reingold, Stephen C., Banwell, Brenda, Clanet, Michel, Cohen, Jeffrey A., Filippi, Massimo, Fujihara, Kazuo, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Lublin, Fred D., Montalban, Xavier, O'Connor, Paul, Sandberg-Wollheim, Magnhild, Thompson, Alan J., Waubant, Emmanuelle, Weinshenker, Brian, Wolinsky, Jerry S.

“…New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of…”
Get full text

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects by Cohen, Jeffrey A, Prof, Reingold, Stephen C, PhD, Polman, Chris H, Prof, Wolinsky, Jerry S, Prof

“…Summary Many of the available disability outcome measures used in clinical trials of multiple sclerosis are insensitive to change over time, inadequately…”
Get full text

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study by Havrdova, Eva, MD, Galetta, Steven, MD, Hutchinson, Michael, MD, Stefoski, Dusan, MD, Bates, David, MD, Polman, Chris H, MD, O'Connor, Paul W, MD, Giovannoni, Gavin, PhD, Phillips, J Theodore, MD, Lublin, Fred D, MD, Pace, Amy, ScD, Kim, Richard, MD, Hyde, Robert, PhD

“…Summary Background The efficacy of natalizumab on clinical and radiological measures in the phase III Natalizumab Safety and Efficacy in Relapsing-Remitting…”
Get full text

Oral treatment for multiple sclerosis by Killestein, Joep, Dr, Rudick, Richard A, Prof, Polman, Chris H, Prof

“…Summary Background The armamentarium for the treatment of relapsing-remitting multiple sclerosis (RRMS) is increasing rapidly. Several oral treatments have…”
Get full text

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study by Kappos, Ludwig, Prof, Freedman, Mark S, Prof, Polman, Chris H, Prof, Edan, Gilles, Prof, Hartung, Hans-Peter, Prof, Miller, David H, Prof, Montalbán, Xavier, Prof, Barkhof, Frederik, Prof, Radü, Ernst-Wilhelm, Prof, Bauer, Lars, MD, Dahms, Susanne, PhD, Lanius, Vivian, PhD, Pohl, Christoph, MD, Sandbrink, Rupert, MD

“…Summary Background Several controlled studies provide evidence that treatment with interferon beta in patients with a first event suggestive of multiple…”
Get full text

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis by Rudick, Richard A, MD, Polman, Chris H, MD

“…Summary Disease-modifying drugs (DMDs) for relapsing-remitting multiple sclerosis (RRMS) are only partly effective—breakthrough disease commonly occurs despite…”
Get full text

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial by Comi, Giancarlo, Prof, De Stefano, Nicola, Prof, Freedman, Mark S, Prof, Barkhof, Frederik, Prof, Polman, Chris H, Prof, Uitdehaag, Bernard MJ, Prof, Casset-Semanaz, Florence, MSc, Hennessy, Brian, MSc, Moraga, Margaretha Stam, MSc, Rocak, Sanda, PhD, Stubinski, Bettina, MD, Kappos, Ludwig, Prof

“…Summary Background In patients presenting with a first clinical demyelinating event that is suggestive of multiple sclerosis (MS), treatment with interferon…”
Get full text

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis by Polman, Chris H, O'Connor, Paul W, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Miller, David H, Phillips, J. Theodore, Lublin, Fred D, Giovannoni, Gavin, Wajgt, Andrzej, Toal, Martin, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…This placebo-controlled, randomized trial of patients with relapsing multiple sclerosis demonstrated benefits of natalizumab (an α 4 integrin antagonist) in…”
Get full text

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" by Polman, Chris H., Reingold, Stephen C., Edan, Gilles, Filippi, Massimo, Hartung, Hans-Peter, Kappos, Ludwig, Lublin, Fred D., Metz, Luanne M., McFarland, Henry F., O'Connor, Paul W., Sandberg-Wollheim, Magnhild, Thompson, Alan J., Weinshenker, Brian G., Wolinsky, Jerry S.

“…New diagnostic criteria for multiple sclerosis integrating magnetic resonance image assessment with clinical and other paraclinical methods were introduced in…”
Get full text

Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients by Lukas, Carsten, Sombekke, Madeleine H, Bellenberg, Barbara, Hahn, Horst K, Popescu, Veronica, Bendfeldt, Kerstin, Radue, Ernst W, Gass, Achim, Borgwardt, Stefan J, Kappos, Ludwig, Naegelin, Yvonne, Knol, Dirk L, Polman, Chris H, Geurts, Jeroen J G, Barkhof, Frederik, Vrenken, Hugo

“…To determine whether spinal cord atrophy differs among disease subtypes in multiple sclerosis (MS) and whether it offers diagnostic and clinical correlative…”
Get full text

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial by Kappos, Ludwig, MD, Freedman, Mark S, MD, Polman, Chris H, MD, Edan, Gilles, MD, Hartung, Hans-Peter, MD, Miller, David H, MD, Montalbán, Xavier, MD, Barkhof, Frederik, MD, Radü, Ernst-Wilhelm, MD, Metzig, Carola, MD, Bauer, Lars, MD, Lanius, Vivian, PhD, Sandbrink, Rupert, MD, Pohl, Christoph, MD

“…Summary Background The Betaferon/Betaseron in newly emerging multiple sclerosis for initial treatment (BENEFIT) trial investigated the effect of treatment with…”
Get full text

Functional brain networks: Linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG Study by Tewarie, Prejaas, Schoonheim, Menno M., Schouten, Daphne I., Polman, Chris H., Balk, Lisanne J., Uitdehaag, Bernard M.J., Geurts, Jeroen J.G., Hillebrand, Arjan, Barkhof, Frederik, Stam, Cornelis J.

“…Thalamic atrophy is known to be one of the most important predictors for clinical dysfunction in multiple sclerosis (MS). As the thalamus is highly connected…”
Get full text

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study by Kappos, Ludwig, Prof, Gold, Ralf, Prof, Miller, David H, Prof, MacManus, David G, MSc, Havrdova, Eva, MD, Limmroth, Volker, MD, Polman, Chris H, Prof, Schmierer, Klaus, PhD, Yousry, Tarek A, MD, Yang, Minhua, MS, Eraksoy, Mefkûre, Prof, Meluzinova, Eva, MD, Rektor, Ivan, MD, Dawson, Katherine T, MD, Sandrock, Alfred W, MD, O'Neill, Gilmore N, MB

“…Summary Background Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of…”
Get full text

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis by Vennegoor, Anke, Rispens, Theo, Strijbis, Eva MM, Seewann, Alexandra, Uitdehaag, Bernard MJ, Balk, Lisanne J, Barkhof, Frederik, Polman, Chris H, Wolbink, Gertjan, Killestein, Joep

“…Background: Antibodies against natalizumab have been found in 4.5–14.1% of natalizumab-treated multiple sclerosis (MS) patients. If antibodies persist, they…”
Get full text

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis by Polman, Chris H, Prof, Bertolotto, Antonio, MD, Deisenhammer, Florian, Prof, Giovannoni, Gavin, Prof, Hartung, Hans-Peter, Prof, Hemmer, Bernhard, Prof, Killestein, Joep, MD, McFarland, Henry F, MD, Oger, Joel, Prof, Pachner, Andrew R, Prof, Petkau, John, Prof, Reder, Anthony T, MD, Reingold, Stephen C, PhD, Schellekens, Huub, Prof, Sørensen, Per Soelberg, Prof

“…Summary The identification of factors that can affect the efficacy of immunomodulatory drugs in relapsing-remitting multiple sclerosis (MS) is important. For…”
Get full text

Disruption of structural and functional networks in long-standing multiple sclerosis by Tewarie, Prejaas, Steenwijk, Martijn D., Tijms, Betty M., Daams, Marita, Balk, Lisanne J., Stam, Cornelis J., Uitdehaag, Bernard M.J., Polman, Chris H., Geurts, Jeroen J.G., Barkhof, Frederik, Pouwels, Petra J.W., Vrenken, Hugo, Hillebrand, Arjan

“…Both gray matter atrophy and disruption of functional networks are important predictors for physical disability and cognitive impairment in multiple sclerosis…”
Get full text

Cognitive and clinical dysfunction, altered MEG resting-state networks and thalamic atrophy in multiple sclerosis by Tewarie, Prejaas, Schoonheim, Menno M, Stam, Cornelis J, van der Meer, Marieke L, van Dijk, Bob W, Barkhof, Frederik, Polman, Chris H, Hillebrand, Arjan

“…The relation between pathological findings and clinical and cognitive decline in Multiple Sclerosis remains unclear. Here, we tested the hypothesis that…”
Get full text

Sex-specific extent and severity of white matter damage in multiple sclerosis: Implications for cognitive decline by Schoonheim, Menno M., Vigeveno, René M., Lopes, Fernanda C. Rueda, Pouwels, Petra J.W., Polman, Chris H., Barkhof, Frederik, Geurts, Jeroen J.G.

“…Cognitive dysfunction is common in multiple sclerosis (MS). However, the relationship between white matter (WM) damage and cognition remains insufficiently…”
Get full text

Improved differentiation between MS and vascular brain lesions using FLAIR at 7 Tesla by Kilsdonk, Iris D., Wattjes, Mike P., Lopez-Soriano, Alexandra, Kuijer, Joost P. A., de Jong, Marcus C., de Graaf, Wolter L., Conijn, Mandy M. A., Polman, Chris H., Luijten, Peter R., Geurts, Jeroen J. G., Geerlings, Mirjam I., Barkhof, Frederik

“…Objectives To investigate whether a new magnetic resonance image (MRI) technique called T2*-weighted fluid attenuation inversion recovery (FLAIR*) can…”
Get full text